Compare EUDA & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | TXMD |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | Singapore | United States |
| Employees | 117 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 24.3M |
| IPO Year | N/A | 2012 |
| Metric | EUDA | TXMD |
|---|---|---|
| Price | $6.67 | $2.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 19.4K |
| Earning Date | 12-19-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $134.73 | N/A |
| Revenue Next Year | $195.03 | N/A |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.33 | $0.98 |
| 52 Week High | $15.36 | $2.95 |
| Indicator | EUDA | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 51.75 |
| Support Level | $2.09 | $2.10 |
| Resistance Level | $15.36 | $2.31 |
| Average True Range (ATR) | 0.74 | 0.13 |
| MACD | -0.51 | 0.02 |
| Stochastic Oscillator | 14.74 | 63.22 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.